DOCSLIB.ORG

Cpg-DNA-Mediated Receptor Activation Site in TLR9 That

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Cpg-DNA-Mediated Receptor Activation Site in TLR9 That Identification of an N-Terminal Recognition Site in TLR9 That Contributes to CpG-DNA-Mediated Receptor Activation This information is current as Mirjam E. Peter, Andriy V. Kubarenko, Alexander N. R. of September 29, 2021. Weber and Alexander H. Dalpke J Immunol 2009; 182:7690-7697; ; doi: 10.4049/jimmunol.0900819 http://www.jimmunol.org/content/182/12/7690 Downloaded from References This article cites 36 articles, 13 of which you can access for free at: http://www.jimmunol.org/content/182/12/7690.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 29, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2009 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Identification of an N-Terminal Recognition Site in TLR9 That Contributes to CpG-DNA-Mediated Receptor Activation1 Mirjam E. Peter,2* Andriy V. Kubarenko,2† Alexander N. R. Weber,3† and Alexander H. Dalpke3* Although it is well established that TLR9 recognizes CpG-DNA, the structural details of ligand-receptor interaction are still mostly unknown. The extracellular domain of TLR9 is composed of 25 leucine-rich repeat (LRR) motifs, 5 of which bear inserting sequences that do not conform to the LRR consensus motif. In this study, we show that the functional integrity of the extracellular domain of murine TLR9 is lost by deletion of individual LRR motifs. When deleting only the inserting sequences, we observed that LRR2, 5, and 8 contribute to receptor activation by CpG-DNA. The latter deletions did not affect receptor dimerization but inhibited CpG-DNA binding. On the basis of a homology modeling approach, we furthermore identify a positively charged region in the N terminus that is essential for CpG-DNA-induced TLR9 activation. This interaction site mirrors findings previously shown for the structural recognition of dsRNA by TLR3 and hints toward a general principle of nucleic acid recognition by the respective Downloaded from TLR. The Journal of Immunology, 2009, 182: 7690–7697. nnate immunity relies on TLR to detect invading microor- sented to the receptor through a binding protein, MD-2 (6). In ganisms (1). TLR are germline-encoded type I integral mem- contrast, the crystal structure of TLR3 bound to dsRNA showed I brane glycoproteins whose extracellular domain (ECD)4 is two binding sites for RNA that are formed by charged patches on responsible for ligand binding. The ECD of TLR is composed of its surface (7–9). One is located in the N-terminal part of the ECD http://www.jimmunol.org/ 19–25 leucine-rich repeats (LRR) (2). Each LRR forms a loop in (involving the LRR-NT and LRR1–3), and the other one is located which conserved hydrophobic residues point inward, and several in the C terminus with the irregular LRR20 contributing to RNA of these loops build-up a horseshoe-shaped ECD, which is N- and binding. Mutational studies confirmed the binding of RNA to res- C-terminally flanked by so-called cysteine flanking regions, idues in a region encompassing LRR20 and deletion of the inser- termed LRR-NT and -CT, respectively. The first 10 aa of LRR are tion in LRR20 led to a complete loss of function (10). conserved in all LRR subtypes and form a ␤-sheet shaping the In contrast to other TLR, the nucleic acid recognizing TLR3, 7, concave surface of the ECD, whereas the remaining portion of the 8, and 9 recognize their ligands in intracellular compartments such LRR is variable among the different subtypes and forms the con- as endosomes. A further noticeable feature of TLR7–9 is that the vex surface. All TLR contain varying numbers of “irregular” LRR irregular LRR of these receptors are located at the same positions by guest on September 29, 2021 that do not entirely conform to the consensus motif but bear in- and that the insertions are very homologous (3). Another similarity serting stretches of amino acids, which protrude from the horse- between these receptors is the presence of a less structured region shoe-shaped backbone and have been proposed to be involved in between LRR14 and 15 with low similarity to the LRR consensus. ligand binding (3). It has been proposed that this region may bring flexibility to the To date, three modes of ligand binding by mammalian TLR receptor (11). In contrast to TLR3, which recognizes dsRNA se- have been identified (4). In the TLR1/TLR2 heterodimer the acyl quence independently (12), TLR7–9 are stimulated by nucleic ac- chains of the Pam3CSK4 ligand are directly inserted into hydro- ids in a sequence-specific manner (13, 14), which implies that in phobic channels stretching LRR9–12 (5). For TLR4, LPS is pre- addition to the general binding characteristics of TLR3 for nucleic acids, recognition by TLR7–9 may be more complex. Surprisingly, for TLR9, it has been recently shown that cleavage of the ECD *Department of Medical Microbiology and Hygiene, University Heidelberg, Heidel- occurs and it was proposed that the C-terminal fragment starting berg, Germany; and †Junior Research Group “Toll-like Receptors and Cancer,” Ger- man Cancer Research Center, Heidelberg, Germany from LRR15 mediates ligand recognition (15, 16). Received for publication March 12, 2009. Accepted for publication April 10, 2009. Whereas receptor dimerization and subsequent signal transduc- tion occur upon ligand binding for TLR2-TLR1 and TLR3, it was The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance published for TLR9 that this receptor exists as a preformed dimer with 18 U.S.C. Section 1734 solely to indicate this fact. (11). Binding of stimulatory DNA was proposed to result in a 1 This study was supported by the German Research Foundation (Deutsche For- conformational change in the receptor, which decreases the diam- schungsgemeinschaft DA592/3 (to A.H.D.); Emmy Noether program (to A.N.R.W.)) eter of the ECD. This process was suggested to bring the TIR and by the German Cancer Research Center (to A.V.K., A.N.R.W.). domains in close proximity, thereby activating downstream sig- 2 M.E.P. and A.V.K. contributed equally. naling. In this study, we tested the hypothesis that insertion-bear- 3 Address correspondence and reprint requests to Dr. Alexander H. Dalpke, De- partment of Medical Microbiology and Hygiene, Hygiene-Institute, University ing LRRs within TLR9 contribute to ligand recognition. Addition- Heidelberg, Im Neuenheimer Feld 324, 69120 Heidelberg, Germany; E-mail ad- ally, we sought to determine whether specific binding sites in the dress: [email protected] or Dr. Alexander N. R. Weber, TLR9 ECD can be mapped. Junior Group “Toll-like Receptors and Cancer,” German Cancer Research Center, Im Neuenheimer Feld 242, 69120 Heidelberg, Germany. E-mail address: [email protected] Materials and Methods 4 Abbreviations used in this paper: ECD, extracellular domain; HA, hemagglutinin; Cells and reagents LRR, leucine-rich repeat; ODN, oligodeoxynucleotide; WT, wild type. CpG-oligodeoxynucleotide (ODN) no. 1668 (TCCATGACGTTCCTGA Copyright © 2009 by The American Association of Immunologists, Inc. 0022-1767/09/$2.00 TGCT) was custom synthesized by MWG-Biotech either 3Ј-biotinylated or www.jimmunol.org/cgi/doi/10.4049/jimmunol.0900819 The Journal of Immunology 7691 unmodified. Resiquimod (R848) was purchased from InvivoGen. LPS from various TLR ligands. After 24 h of stimulation, TNF-␣ was determined in Salmonella minnesota was provided by U. Seydel (Research Center Bor- cell-free supernatants by ELISA, according to the manufacturer’s instruc- stel, Borstel, Germany). DMEM, RPMI 1640 medium, and FCS were pur- tion, and fresh media were added to the cells. Other 24 h later supernatants chased from Biochrom. Abs were received from Cell Signaling Technol- were analyzed for NO accumulation photometrically (550 nm) by mixing ogy. Immobilized protein A was obtained from Thermo Scientific, equal parts of supernatant and Griess reagent (1:1 mixture of 1% sulfanil- streptavidin-agarose was from Prozyme, and the cathepsin inhibitor z-FA- amide/5% H3PO4 and 0.1% naphthyl-ethylenediamine dihydrochloride). fmk was from Biovision. RAW 264.7 cells, a murine macrophage cell line, were a gift from R. Schumann (Institute for Microbiology and Hygiene, Homology modeling and structure analysis Berlin, Germany). HEK293 cells were obtained from S. Bauer (Institute for Immunology, Marburg, Germany). Homology modeling of mouse TLR9 ECD was conducted as previously described (18) based on the published human TLR3 ECD crystal struc- Site-directed mutagenesis tures (7, 19). In brief, the TLR9 ECD was generated stepwise by mod- eling N- and C-terminal subdomains and LRR14 individually using the mTLR9-HA-plasmid was constructed by replacing the YFP-tag in TLR9- MODELLER package (20). These were manually assembled, and spa- YFP (obtained by T. Espevik, Institute of Cancer Research and Molecular tial violations resulting from the manual docking procedure were cor- Medicine, Trondheim, Norway) with an HA-tag, using the restriction en- rected using GROMACS molecular dynamics (21). The complete ECD Ј zymes XhoI and Bsp1407I and custom synthesized 5 -phosphorylated model was then scored for energy and sterical correctness using the ODN encoding the hemagglutinin (HA)-tag sequence YPYDVPDYA.
Load more

Recommended publications
  • TLR3-Dependent Activation of TLR2 Endogenous Ligands Via the Myd88 Signaling Pathway Augments the Innate Immune Response
    cells Article TLR3-Dependent Activation of TLR2 Endogenous Ligands via the MyD88 Signaling Pathway Augments the Innate Immune Response 1 2, 1 3 Hellen S. Teixeira , Jiawei Zhao y, Ethan Kazmierski , Denis F. Kinane and Manjunatha R. Benakanakere 2,* 1 Department of Orthodontics, School of Dental Medicine, University of Pennsylvania, Philadelphia, PA 19004, USA; [email protected] (H.S.T.); [email protected] (E.K.) 2 Department of Periodontics, School of Dental Medicine, University of Pennsylvania, Philadelphia, PA 19004, USA; [email protected] 3 Periodontology Department, Bern Dental School, University of Bern, 3012 Bern, Switzerland; [email protected] * Correspondence: [email protected] Present address: Department of Pathology, Wayne State University School of Medicine, y 541 East Canfield Ave., Scott Hall 9215, Detroit, MI 48201, USA. Received: 30 June 2020; Accepted: 12 August 2020; Published: 17 August 2020 Abstract: The role of the adaptor molecule MyD88 is thought to be independent of Toll-like receptor 3 (TLR3) signaling. In this report, we demonstrate a previously unknown role of MyD88 in TLR3 signaling in inducing endogenous ligands of TLR2 to elicit innate immune responses. Of the various TLR ligands examined, the TLR3-specific ligand polyinosinic:polycytidylic acid (poly I:C), significantly induced TNF production and the upregulation of other TLR transcripts, in particular, TLR2. Accordingly, TLR3 stimulation also led to a significant upregulation of endogenous TLR2 ligands mainly, HMGB1 and Hsp60. By contrast, the silencing of TLR3 significantly downregulated MyD88 and TLR2 gene expression and pro-inflammatory IL1β, TNF, and IL8 secretion. The silencing of MyD88 similarly led to the downregulation of TLR2, IL1β, TNF and IL8, thus suggesting MyD88 / to somehow act downstream of TLR3.
    [Show full text]
  • TLR4 and TLR9 Ligands Macrophages Induces Cross
    Lymphotoxin β Receptor Activation on Macrophages Induces Cross-Tolerance to TLR4 and TLR9 Ligands This information is current as Nadin Wimmer, Barbara Huber, Nicola Barabas, Johann of September 27, 2021. Röhrl, Klaus Pfeffer and Thomas Hehlgans J Immunol 2012; 188:3426-3433; Prepublished online 22 February 2012; doi: 10.4049/jimmunol.1103324 http://www.jimmunol.org/content/188/7/3426 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2012/02/23/jimmunol.110332 Material 4.DC1 http://www.jimmunol.org/ References This article cites 42 articles, 13 of which you can access for free at: http://www.jimmunol.org/content/188/7/3426.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision by guest on September 27, 2021 • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2012 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Lymphotoxin b Receptor Activation on Macrophages Induces Cross-Tolerance to TLR4 and TLR9 Ligands Nadin Wimmer,* Barbara Huber,* Nicola Barabas,* Johann Ro¨hrl,* Klaus Pfeffer,† and Thomas Hehlgans* Our previous studies indicated that lymphotoxin b receptor (LTbR) activation controls and downregulates inflammatory reac- tions.
    [Show full text]
  • Regulation of Neuronal Morphogenesis and Brain Functions Via Toll-Like Receptors Chiung-Ya Chen*, Yi-Chun Shih, Yun-Fen Hung and Yi-Ping Hsueh*
    Chen et al. Journal of Biomedical Science (2019) 26:90 https://doi.org/10.1186/s12929-019-0584-z REVIEW Open Access Beyond defense: regulation of neuronal morphogenesis and brain functions via Toll-like receptors Chiung-Ya Chen*, Yi-Chun Shih, Yun-Fen Hung and Yi-Ping Hsueh* Abstract Toll-like receptors (TLRs) are well known as critical pattern recognition receptors that trigger innate immune responses. In addition, TLRs are expressed in neurons and may act as the gears in the neuronal detection/alarm system for making good connections. As neuronal differentiation and circuit formation take place along with programmed cell death, neurons face the challenge of connecting with appropriate targets while avoiding dying or dead neurons. Activation of neuronal TLR3, TLR7 and TLR8 with nucleic acids negatively modulates neurite outgrowth and alters synapse formation in a cell-autonomous manner. It consequently influences neural connectivity and brain function and leads to deficits related to neuropsychiatric disorders. Importantly, neuronal TLR activation does not simply duplicate the downstream signal pathways and effectors of classical innate immune responses. The differences in spatial and temporal expression of TLRs and their ligands likely account for the diverse signaling pathways of neuronal TLRs. In conclusion, the accumulated evidence strengthens the idea that the innate immune system of neurons serves as an alarm system that responds to exogenous pathogens as well as intrinsic danger signals and fine-tune developmental processes of neurons. Keywords: Innate immunity, TLR, Neuronal development Introduction innate immune system responds quickly to danger sig- Organisms have host defense systems, namely adaptive nals and lacks antigen specificity.
    [Show full text]
  • B Cells Expression in Follicular and Marginal Zone TLR Stimulation
    TLR Stimulation Modifies BLyS Receptor Expression in Follicular and Marginal Zone B Cells This information is current as Laura S. Treml, Gianluca Carlesso, Kristen L. Hoek, Jason of October 2, 2021. E. Stadanlick, Taku Kambayashi, Richard J. Bram, Michael P. Cancro and Wasif N. Khan J Immunol 2007; 178:7531-7539; ; doi: 10.4049/jimmunol.178.12.7531 http://www.jimmunol.org/content/178/12/7531 Downloaded from References This article cites 57 articles, 25 of which you can access for free at: http://www.jimmunol.org/content/178/12/7531.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on October 2, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2007 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology TLR Stimulation Modifies BLyS Receptor Expression in Follicular and Marginal Zone B Cells1 Laura S. Treml,2* Gianluca Carlesso,2† Kristen L. Hoek,† Jason E. Stadanlick,* Taku Kambayashi,* Richard J.
    [Show full text]
  • TLR9 Gene Transcriptional Regulation of the Human
    Transcriptional Regulation of the Human TLR9 Gene Fumihiko Takeshita, Koichi Suzuki, Shin Sasaki, Norihisa Ishii, Dennis M. Klinman and Ken J. Ishii This information is current as of September 30, 2021. J Immunol 2004; 173:2552-2561; ; doi: 10.4049/jimmunol.173.4.2552 http://www.jimmunol.org/content/173/4/2552 Downloaded from References This article cites 49 articles, 31 of which you can access for free at: http://www.jimmunol.org/content/173/4/2552.full#ref-list-1 Why The JI? Submit online. http://www.jimmunol.org/ • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average by guest on September 30, 2021 Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2004 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Transcriptional Regulation of the Human TLR9 Gene1 Fumihiko Takeshita,2* Koichi Suzuki,† Shin Sasaki,‡ Norihisa Ishii,‡ Dennis M. Klinman,* and Ken J. Ishii3* To clarify the molecular basis of human TLR9 (hTLR9) gene expression, the activity of the hTLR9 gene promoter was charac- terized using the human myeloma cell line RPMI 8226.
    [Show full text]
  • Combined Carriership of TLR9 -1237C and CD14 -260T Alleles Enhances the Risk of Developing Chronic Relapsing Pouchitis
    CORE Metadata, citation and similar papers at core.ac.uk Provided by DSpace at VU PO Box 2345, Beijing 100023, China World J Gastroenterol 2005;11(46):7323-7329 www.wjgnet.com World Journal of Gastroenterology ISSN 1007-9327 [email protected] © 2005 The WJG Press and Elsevier Inc. All rights reserved. ELSEVIER • RAPID COMMUNICATION • Combined carriership of TLR9 -1237C and CD14 -260T alleles enhances the risk of developing chronic relapsing pouchitis KM Lammers, S Ouburg, SA Morré, JBA Crusius, P Gionchetti, F Rizzello, C Morselli, E Caramelli, R Conte, G Poggioli, M Campieri, AS Peña KM Lammers, P Gionchetti, F Rizzello, C Morselli, M CONCLUSION: There is no evidence that the SNPs Campieri, Department of Internal Medicine and Gastroenterology, predispose to the need for IPAA surgery. The signifi cant Policlinico S. Orsola, University of Bologna, Bologna, Italy increase of the combined carriership of the CD14 S Ouburg, SA Morré, JBA Crusius, AS Peña, Laboratory of -260T and TLR9 -1237C alleles in the chronic relapsing Immunogenetics, VU University Medical Center, Amsterdam, The pouchitis group suggests that these markers identify Netherlands a subgroup of IPAA patients with a risk of developing E Caramelli, Institute of Histology and General Embryology, University of Bologna, Bologna, Italy chronic or refractory pouchitis. R Conte, Department of Immunohaematology and Blood Transfusion, Policlinico S. Orsola, University of Bologna, © 2005 The WJG Press and Elsevier Inc. All rights reserved. Bologna, Italy AS Peña, Laboratory of Immunogenetics and Department of Key words: Pouchitis; Innate immunity; Single nucleotide Gastroenterology, VU University Medical Center, Amsterdam, polymorphisms; CD14 ; TLR9 The Netherlands G Poggioli, Department of Surgery and Organ Transplantation, Lammers KM, Ouburg S, Morré SA, Crusius JBA, Gionchetti Policlinic S.
    [Show full text]
  • FAS (CD95) Mediates Noncanonical IL-1 Β and IL-18 Maturation Via Caspase-8 in an RIP3-Independent Manner This Information Is Current As of September 26, 2021
    Cutting Edge: FAS (CD95) Mediates Noncanonical IL-1 β and IL-18 Maturation via Caspase-8 in an RIP3-Independent Manner This information is current as of September 26, 2021. Lukas Bossaller, Ping-I Chiang, Christian Schmidt-Lauber, Sandhya Ganesan, William J. Kaiser, Vijay A. K. Rathinam, Edward S. Mocarski, Deepa Subramanian, Douglas R. Green, Neal Silverman, Katherine A. Fitzgerald, Ann Marshak-Rothstein and Eicke Latz Downloaded from J Immunol 2012; 189:5508-5512; Prepublished online 9 November 2012; doi: 10.4049/jimmunol.1202121 http://www.jimmunol.org/content/189/12/5508 http://www.jimmunol.org/ Supplementary http://www.jimmunol.org/content/suppl/2012/11/12/jimmunol.120212 Material 1.DC1 References This article cites 30 articles, 9 of which you can access for free at: http://www.jimmunol.org/content/189/12/5508.full#ref-list-1 by guest on September 26, 2021 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2012 by The American Association of Immunologists, Inc. All rights reserved.
    [Show full text]
  • TLR3 Controls Constitutive IFN-Β Antiviral Immunity in Human Fibroblasts and Cortical Neurons
    TLR3 controls constitutive IFN-β antiviral immunity in human fibroblasts and cortical neurons Daxing Gao, … , Jean-Laurent Casanova, Shen-Ying Zhang J Clin Invest. 2021;131(1):e134529. https://doi.org/10.1172/JCI134529. Research Article Immunology Infectious disease Graphical abstract Find the latest version: https://jci.me/134529/pdf The Journal of Clinical Investigation RESEARCH ARTICLE TLR3 controls constitutive IFN-β antiviral immunity in human fibroblasts and cortical neurons Daxing Gao,1,2,3 Michael J. Ciancanelli,1,4 Peng Zhang,1 Oliver Harschnitz,5,6 Vincent Bondet,7 Mary Hasek,1 Jie Chen,1 Xin Mu,8 Yuval Itan,9,10 Aurélie Cobat,11,12 Vanessa Sancho-Shimizu,11,12,13 Benedetta Bigio,1 Lazaro Lorenzo,11,12 Gabriele Ciceri,5,6 Jessica McAlpine,5,6 Esperanza Anguiano,14 Emmanuelle Jouanguy,1,11,12 Damien Chaussabel,14,15,16 Isabelle Meyts,17,18,19 Michael S. Diamond,20 Laurent Abel,1,11,12 Sun Hur,8 Gregory A. Smith,21 Luigi Notarangelo,22 Darragh Duffy,7 Lorenz Studer,5,6 Jean-Laurent Casanova,1,11,12,23,24 and Shen-Ying Zhang1,11,12 1St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, New York, USA. 2Department of General Surgery, The First Affiliated Hospital of USTC, and 3Hefei National Laboratory for Physical Sciences at Microscale, the CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China. 4Turnstone Biologics, New York, New York, USA.
    [Show full text]
  • TLR Signaling Pathways
    Seminars in Immunology 16 (2004) 3–9 TLR signaling pathways Kiyoshi Takeda, Shizuo Akira∗ Department of Host Defense, Research Institute for Microbial Diseases, Osaka University, and ERATO, Japan Science and Technology Corporation, 3-1 Yamada-oka, Suita, Osaka 565-0871, Japan Abstract Toll-like receptors (TLRs) have been established to play an essential role in the activation of innate immunity by recognizing spe- cific patterns of microbial components. TLR signaling pathways arise from intracytoplasmic TIR domains, which are conserved among all TLRs. Recent accumulating evidence has demonstrated that TIR domain-containing adaptors, such as MyD88, TIRAP, and TRIF, modulate TLR signaling pathways. MyD88 is essential for the induction of inflammatory cytokines triggered by all TLRs. TIRAP is specifically involved in the MyD88-dependent pathway via TLR2 and TLR4, whereas TRIF is implicated in the TLR3- and TLR4-mediated MyD88-independent pathway. Thus, TIR domain-containing adaptors provide specificity of TLR signaling. © 2003 Elsevier Ltd. All rights reserved. Keywords: TLR; Innate immunity; Signal transduction; TIR domain 1. Introduction 2. Toll-like receptors Toll receptor was originally identified in Drosophila as an A mammalian homologue of Drosophila Toll receptor essential receptor for the establishment of the dorso-ventral (now termed TLR4) was shown to induce the expression pattern in developing embryos [1]. In 1996, Hoffmann and of genes involved in inflammatory responses [3]. In addi- colleagues demonstrated that Toll-mutant flies were highly tion, a mutation in the Tlr4 gene was identified in mouse susceptible to fungal infection [2]. This study made us strains that were hyporesponsive to lipopolysaccharide [4]. aware that the immune system, particularly the innate im- Since then, Toll receptors in mammals have been a major mune system, has a skilful means of detecting invasion by focus in the immunology field.
    [Show full text]
  • Human Cancer Cells TLR3 Can Directly Trigger Apoptosis In
    TLR3 Can Directly Trigger Apoptosis in Human Cancer Cells Bruno Salaun, Isabelle Coste, Marie-Clotilde Rissoan, Serge J. Lebecque and Toufic Renno This information is current as of September 27, 2021. J Immunol 2006; 176:4894-4901; ; doi: 10.4049/jimmunol.176.8.4894 http://www.jimmunol.org/content/176/8/4894 Downloaded from References This article cites 44 articles, 17 of which you can access for free at: http://www.jimmunol.org/content/176/8/4894.full#ref-list-1 Why The JI? Submit online. http://www.jimmunol.org/ • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average by guest on September 27, 2021 Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2006 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology TLR3 Can Directly Trigger Apoptosis in Human Cancer Cells1 Bruno Salaun,2 Isabelle Coste,2 Marie-Clotilde Rissoan, Serge J. Lebecque,3 and Toufic Renno TLRs function as molecular sensors to detect pathogen-derived products and trigger protective responses ranging from secretion of cytokines that increase the resistance of infected cells and chemokines that recruit immune cells to cell death that limits microbe spreading.
    [Show full text]
  • Toll-Like Receptors and Relevant Emerging Therapeutics with Reference to Delivery Methods
    pharmaceutics Review Toll-Like Receptors and Relevant Emerging Therapeutics with Reference to Delivery Methods Nasir Javaid, Farzana Yasmeen and Sangdun Choi * Department of Molecular Science and Technology, Ajou University, Suwon 16499, Korea * Correspondence: [email protected]; Tel.: +82-31-219-2600 Received: 9 July 2019; Accepted: 28 August 2019; Published: 1 September 2019 Abstract: The built-in innate immunity in the human body combats various diseases and their causative agents. One of the components of this system is Toll-like receptors (TLRs), which recognize structurally conserved molecules derived from microbes and/or endogenous molecules. Nonetheless, under certain conditions, these TLRs become hypofunctional or hyperfunctional, thus leading to a disease-like condition because their normal activity is compromised. In this regard, various small-molecule drugs and recombinant therapeutic proteins have been developed to treat the relevant diseases, such as rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, systemic lupus erythematosus, and allergy. Some drugs for these diseases have been clinically approved; however, their efficacy can be enhanced by conventional or targeted drug delivery systems. Certain delivery vehicles such as liposomes, hydrogels, nanoparticles, dendrimers, or cyclodextrins can be employed to enhance the targeted drug delivery. This review summarizes the TLR signaling pathway, associated diseases and their treatments, and the ways to efficiently deliver the drugs to a target site. Keywords: Toll-like receptor; immunological disease; therapeutic; drug delivery method 1. Introduction The immune system in an organism is the protective system combating pathogenic and/or abnormal conditions. Innate and adaptive immune systems are two basic components in vertebrates. Adaptive immunity is mediated by T and B lymphocytes with the help of their antigen-specific receptors that are encoded as a result of hypermutability and rearrangements in a genomic region of the organism.
    [Show full text]
  • Human TLR1-9 Agonist Kit Set of Known Agonists for Human TLR1 to TLR9 Catalog Code: Tlrl-Kit1hw
    Human TLR1-9 Agonist Kit Set of known agonists for human TLR1 to TLR9 Catalog code: tlrl-kit1hw https://www.invivogen.com/human-tlr1-9-agonist-kit For research use only Version 19B14-MM PRODUCT INFORMATION • Poly(I:C) HMW and Poly(I:C) LMW - TLR3 agonists Contents Poly(I:C) is a synthetic analog of double-stranded RNA (dsRNA), • TLR1/2 agonist - Pam3CSK4 (10 µg) a molecular pattern associated with viral infection. Poly(I:C) is • TLR2 agonist - HKLM (109 cells) composed of a strand of poly(I) annealed to a strand of poly(C). • TLR3 agonist - Poly(I:C) HMW (500 µg) The size of the strands varies. Poly(I:C) HMW has a high • TLR3 agonist - Poly(I:C) LMW (500 µg) molecular weight (average size 1.5-8 kb), whereas Poly(I:C) • TLR4 agonist - LPS-EK standard (100 µg) LMW has a low molecular weight (average size 0.2-1 kb). • TLR5 agonist - FLA-ST standard(10 µg) Poly(I:C) HMW and Poly(I:C) LMW may activate the immune • TLR6/2 agonist - FSL-1 (10 µg) system differently. dsRNA is known to induce interferons (IFNs) • TLR7 agonist - Imiquimod (25 µg) and other cytokines production. IFN induction is mediated by • TLR8 agonist - ssRNA40 (25 µg) two different pathways. The first pathway leading to NF-κB • TLR9 agonist - ODN2006 (100 µg - 12.98 nmol) activation depends on the dsRNA-responsive protein kinase • 2 x 2 ml endotoxin-free water (PKR)5, whereas the second pathway is PKR-independent and involves TLR36. Storage and stability - Products are shipped at room temperature and should be stored • LPS from E.
    [Show full text]